Psychosocial Services/Management of Depression

Feb 15, 2017 by in ONCOLOGY Comments Off on Psychosocial Services/Management of Depression

Antidepressant Suggested target dosage range Common side effects and cautions Bupropion 200–400 mg divided (or bupropion extended release once daily) Anxiety, agitation, headache, nausea, insomnia, seizures (rare) Citalopram 20–40 mg…

read more

Genetic Counseling and Risk Assessment

Feb 15, 2017 by in ONCOLOGY Comments Off on Genetic Counseling and Risk Assessment

Knowledge 1. Understand basic human genetics terminology 2. Understand the basic patterns of biological inheritance and variation, both within families and within populations 3. Understand how identification of disease-associated genetic…

read more

Symptom Management: Weight Gain

Feb 15, 2017 by in ONCOLOGY Comments Off on Symptom Management: Weight Gain

© Springer International Publishing Switzerland 2016David Alberts, Maria Lluria-Prevatt, Stephanie Kha and Karen Weihs (eds.)Supportive Cancer Care10.1007/978-3-319-24814-1_14 14. Symptom Management: Weight Gain Jennifer W. Bea1  , Hendrik D. De Heer2   and Anna L. Schwartz3, 4, 5   (1) Department of Medicine and Nutritional Sciences, University of…

read more

Nutrition and the Cancer Survivor

Feb 15, 2017 by in ONCOLOGY Comments Off on Nutrition and the Cancer Survivor

Maintain a healthy body weight >5 servings vegetables/fruit daily Select low-fat foods Select high-fiber foods Reduce intake of simple sugars/refined CHO/fructose Limit red meat (18 oz./week); avoid processed/charcoaled/well-done meat or…

read more

Fatigue

Feb 15, 2017 by in ONCOLOGY Comments Off on Fatigue

Fig. 10.1 Contributing factors to cancer-related fatigue (Reproduced with permission from Mortimer et al. [1]) There is a direct correlation between treatment and fatigue, with different treatment modalities such as…

read more

Delayed Nausea/Emesis

Feb 15, 2017 by in ONCOLOGY Comments Off on Delayed Nausea/Emesis

Emetic risk category Phase Guideline recommendations MASCC/EMSO NCCN ASCO I. High (>90 %) risk Acute 5-HT3RA (palonosetron) + DMZ + APR (or FOS) 5-HT3RAa + DMZ (12 mg) + APR (125 mg) 5-HT3RA (palonosetron) + DMZ + APR Delayed DMZ + APR DMZ (8…

read more

Breakthrough Cancer Pain

Feb 15, 2017 by in ONCOLOGY Comments Off on Breakthrough Cancer Pain

National Comprehensive Cancer Network “Episodic pain not controlled with [an] existing pain regimen” [6] Oxford Textbook of Palliative Medicine “A transitory exacerbation of pain experienced by the patient who has…

read more

Introduction

Feb 15, 2017 by in ONCOLOGY Comments Off on Introduction

© Springer International Publishing Switzerland 2016David Alberts, Maria Lluria-Prevatt, Stephanie Kha and Karen Weihs (eds.)Supportive Cancer Care10.1007/978-3-319-24814-1_1 1. Introduction David Alberts1  , Maria Lluria-Prevatt2  , Stephanie Kha2   and Karen Weihs2   (1) College of Medicine, University of Arizona, Tucson, AZ, USA (2) University of…

read more

Fundamentals of Cancer Pain Management

Feb 15, 2017 by in ONCOLOGY Comments Off on Fundamentals of Cancer Pain Management

Method Application Effectiveness Comments and references Opioids Somatic pain Neuropathic pain Mixed pain  In one underpowered randomized trial, methadone had no more effect than morphine in neuropathic pain Adjuvant drugs…

read more
Get Clinical Tree app for offline access